Nathan Timothy R, Whitelaw Douglas E, Chang Stanley C, Lees William R, Ripley Paul M, Payne Heather, Jones Linda, Parkinson M Constance, Emberton Mark, Gillams Alison R, Mundy Anthony R, Bown Stephen G
National Medical Laser Center, Department of Surgery and Institute of Urology, Royal and Free University College Medical School, London, United Kingdom.
J Urol. 2002 Oct;168(4 Pt 1):1427-32. doi: 10.1016/S0022-5347(05)64466-7.
Photodynamic therapy, using a photosensitizing drug activated by red light, can destroy localized areas of cancer with safe healing and without the cumulative toxicity associated with ionizing radiation. We used photodynamic therapy in a phase I-II study to treat patients with locally recurrent prostate cancer after radiotherapy.
Patients with an increasing prostate specific antigen (PSA) and biopsy proven local recurrence after radiotherapy were offered photodynamic therapy. Three days after intravenous administration of the photosensitizer meso-tetrahydroxyphenyl chlorin, light was applied using optical fibers inserted percutaneously through perineal needles positioned in the prostate with imaging guidance. Patients were followed with PSA measurements, prostate biopsies, computerized tomography or magnetic resonance imaging and questionnaires on urinary and sexual function.
Photodynamic therapy was given to 14 men using high light doses in 13. Treatment was well tolerated. PSA decreased in 9 patients (to undetectable levels in 2) and 5 had no viable tumor on posttreatment biopsies. After photodynamic therapy, contrast enhanced computerized tomography or magnetic resonance imaging showed necrosis involving up to 91% of the prostate cross section. In 4 men stress incontinence developed (troublesome in 2 and mild in 2) which is slowly improving. Sexual potency was impaired in 4 of the 7 men able to have intercourse before photodynamic therapy, which did not improve. There were no rectal complications directly related to photodynamic therapy, but in 1 patient a urethrorectal fistula developed following an ill-advised rectal biopsy 1 month after therapy.
Photodynamic therapy is a new option that could be suitable for organ confined prostate cancer recurrence after radiotherapy. With more precise light dosimetry, it may be possible to destroy essentially all glandular tissue within the prostate with few complications. These results suggest that photodynamic therapy merits further investigation.
光动力疗法利用红光激活的光敏药物,能够安全治愈且无电离辐射相关的累积毒性地破坏局部癌症区域。我们在一项I-II期研究中使用光动力疗法治疗放疗后局部复发的前列腺癌患者。
为前列腺特异性抗原(PSA)升高且活检证实放疗后局部复发的患者提供光动力疗法。静脉注射光敏剂中-四羟基苯基氯卟啉三天后,在影像引导下经会阴针经皮插入前列腺,通过光纤施加光照。通过PSA测量、前列腺活检、计算机断层扫描或磁共振成像以及关于泌尿和性功能的问卷调查对患者进行随访。
14名男性接受了光动力疗法,其中13名使用了高剂量光照。治疗耐受性良好。9名患者的PSA下降(2名降至无法检测水平),5名患者在治疗后活检中无存活肿瘤。光动力疗法后,增强计算机断层扫描或磁共振成像显示坏死累及前列腺横截面高达91%。4名男性出现压力性尿失禁(2名严重,2名轻度),且正在缓慢改善。在光动力疗法前能够进行性交的7名男性中,4名的性功能受损,且未改善。没有与光动力疗法直接相关的直肠并发症,但1名患者在治疗后1个月进行了不当的直肠活检后出现了尿道直肠瘘。
光动力疗法是一种新的选择,可能适用于放疗后器官局限性前列腺癌复发。通过更精确的光剂量测定,有可能基本上破坏前列腺内所有腺组织且并发症极少。这些结果表明光动力疗法值得进一步研究。